Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: schaap n. Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. Haematologica. 2015. PMID: 26341740 Free PMC article. Clinical Trial. No abstract available.
Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival.
Levenga H, Levison-Keating S, Schattenberg AV, Dolstra H, Schaap N, Raymakers RA. Levenga H, et al. Among authors: schaap n. Bone Marrow Transplant. 2007 Aug;40(4):355-9. doi: 10.1038/sj.bmt.1705742. Epub 2007 Jun 11. Bone Marrow Transplant. 2007. PMID: 17563732 Clinical Trial.
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, de Witte T, Dolstra H, Raymakers R. Levenga H, et al. Among authors: schaap n. Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14. Biol Blood Marrow Transplant. 2010. PMID: 19835972 Free article. Clinical Trial.
Thalidomide and lenalidomide in primary myelofibrosis.
Holle N, de Witte T, Mandigers C, Schaap N, Raymakers R. Holle N, et al. Among authors: schaap n. Neth J Med. 2010 Aug;68(1):293-8. Neth J Med. 2010. PMID: 20739725 Free article. Review.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: schaap n. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22. Blood. 2012. PMID: 22442350 Free article. Clinical Trial.
Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H. Hobo W, et al. Among authors: schaap n. Cancer Immunol Immunother. 2013 Aug;62(8):1381-92. doi: 10.1007/s00262-013-1438-2. Epub 2013 Jun 2. Cancer Immunol Immunother. 2013. PMID: 23728352 Free PMC article. Clinical Trial.
Immunotherapeutic approaches to treat multiple myeloma.
Roeven MW, Hobo W, Schaap N, Dolstra H. Roeven MW, et al. Among authors: schaap n. Hum Vaccin Immunother. 2014;10(4):896-910. doi: 10.4161/hv.27380. Epub 2013 Dec 11. Hum Vaccin Immunother. 2014. PMID: 24335570 Free PMC article. Review.
Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C, Göhring G, de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N; MDS subcommittee of the Chronic Malignancies Working Party of the EBMT. Koenecke C, et al. Among authors: schaap n. Haematologica. 2015 Mar;100(3):400-8. doi: 10.3324/haematol.2014.116715. Epub 2014 Dec 31. Haematologica. 2015. PMID: 25552702 Free PMC article.
159 results